Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brent Geissinger

Gastroenterology Virginia Beach, VA Medical Doctor

NPI 1821079146 CMS profile 127652

1020 Independence Blvd, Suite 110, Virginia Beach, VA 23455

Open in the dashboard

General payments

$11,604

628 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brent Geissinger of Virginia Beach, VA is reported in the CMS Open Payments database as having received $11,604 across 628 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,219 102
2024 General $2,494 117
2023 General $2,080 128
2022 General $1,703 110
2021 General $539 33
2020 General $408 25
2019 General $2,159 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brent Geissinger
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Brent Geissinger were reported at $2,219. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Brent Geissinger Gastroenterology median Middle half National median
2019 $2,159 $417 $126–$1,100 $163
2020 $408 $224 $74–$624 $114
2021 $539 $352 $106–$1,054 $132
2022 $1,703 $448 $129–$1,270 $149
2023 $2,080 $533 $150–$1,390 $160
2024 $2,494 $605 $160–$1,606 $164
2025 $2,219 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,737 178 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,307 71 payments
  3. Gilead Sciences, Inc. $1,137 57 payments
  4. Janssen Biotech, Inc. $1,025 56 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $969 53 payments
  6. QOL Medical, LLC $627 24 payments
  7. Celgene Corporation $423 31 payments
  8. Regeneron Healthcare Solutions, Inc. $383 16 payments
  9. Ardelyx, Inc. $381 18 payments
  10. Merck Sharp & Dohme Corporation $298 14 payments
  11. Other $2,317 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,560 626 payments
  2. Education $43 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,371 87 payments
  2. XIFAXAN $1,061 52 payments
  3. STELARA $894 51 payments
  4. HUMIRA $860 53 payments
  5. ENTYVIO $660 32 payments
  6. SKYRIZI Immunology $641 45 payments
  7. SKYRIZI Immunology $579 32 payments
  8. ZEPOSIA $478 33 payments
  9. SIMPONI $469 27 payments
  10. SIMPONI ARIA $389 21 payments
  11. Other $6,258 319 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,127

Median for Gastroenterology: 569

Drug cost

$520,046

Median for Gastroenterology: $104,976

Branded share of claims

39.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 28 $108,400
Ocaliva Obeticholic Acid Brand 11 $105,564
Linzess Linaclotide Brand 89 $97,016
Humira(Cf) Pen Adalimumab Brand 12 $76,260
Xifaxan Rifaximin Brand 20 $59,065
Trulance Plecanatide Brand 11 $16,551
Mesalamine Generic 18 $10,600
Movantik Naloxegol Oxalate Brand 13 $8,440
Dexlansoprazole Dr Dexlansoprazole Brand 36 $6,487
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 37 $5,335

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$173,215

Medicare's payments for the services billed

Medicare patients

641

Average age 73

Services billed

1,177

319 women, 322 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 35%
Ischemic heart disease 28%
Chronic kidney disease 26%
COPD 24%
Depression 24%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $281
$281 20 —
RINVOQ
  • AbbVie, Inc. $221
$221 — —
Sucraid
  • QOL Medical, LLC $207
$207 — —
SKYRIZI
  • AbbVie, Inc. $186
$186 — —
STELARA
  • Janssen Biotech, Inc. $171
$171 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

628 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record